miltefosine has been researched along with Hypersensitivity in 2 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Hypersensitivity: Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weller, K | 1 |
| Artuc, M | 1 |
| Jennings, G | 2 |
| Friedrichson, T | 1 |
| Guhl, S | 1 |
| dos Santos, RV | 1 |
| Sünder, C | 1 |
| Zuberbier, T | 1 |
| Maurer, M | 1 |
| Bäumer, W | 1 |
| Wlaź, P | 1 |
| Rundfeldt, C | 1 |
1 trial available for miltefosine and Hypersensitivity
| Article | Year |
|---|---|
Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo.
Topics: Antineoplastic Agents; Humans; Hypersensitivity; In Vitro Techniques; Inflammation Mediators; Mast C | 2009 |
1 other study available for miltefosine and Hypersensitivity
| Article | Year |
|---|---|
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; | 2010 |